Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

医学 无容量 易普利姆玛 临床终点 内科学 肿瘤科 肝细胞癌 实体瘤疗效评价标准 不利影响 临床研究阶段 随机对照试验 临床试验 外科 免疫疗法 癌症
作者
Aditya Juloori,Rohan Reddy Katipally,Jeffrey M. Lemons,Anurag K. Singh,Renuka V. Iyer,Jared Rex Robbins,Ben George,William A. Hall,Sean P. Pitroda,Fauzia Arif,John J. Fung,Anjana A Pillai,Chih‐Yi Liao,Manish R. Sharma,Stanley L. Liauw
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:115 (1): 202-213 被引量:95
标识
DOI:10.1016/j.ijrobp.2022.09.052
摘要

Immunotherapy has emerged as a promising therapeutic option for advanced or unresectable hepatocellular carcinoma (HCC). However, survival remains poor with only a subset of patients deriving benefit. This trial investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in HCC.In this multicenter phase 1 randomized trial, patients with advanced or unresectable HCC received liver SBRT (40 Gy in 5 fractions) followed by either nivolumab alone or nivolumab plus ipilimumab. The primary endpoint was dose-limiting toxicity occurring within 6 months of SBRT. Secondary endpoints included overall response rate, progression-free survival, overall survival (OS), distant disease control, and local control of the irradiated tumor. Disease status and response endpoints were assessed radiographically every 8 weeks until progression or initiation of nonprotocol therapy. Response was determined using both RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 and iRECIST.Fourteen patients were enrolled across 3 centers. Thirteen patients were evaluated for study endpoints. The study was closed early because of slow accrual. The median follow-up time was 42.7 months. Dose-limiting toxicities within 6 months occurred in 2 (15.4%) of 13 patients: 1 of 6 patients in the nivolumab arm (16.7%; 90% confidence interval [CI], 0.9%-58.2%) and 1 of 7 patients in the nivolumab plus ipilimumab arm (14.3%; 90% CI, 0.7%-52.1%). Grade 3 adverse events occurred in 8 (61.6%), 5 (71.4%), and 3 (50.0%) patients in the overall nivolumab plus ipilimumab and nivolumab cohorts. Grade 3 hepatotoxicity occurred in 4 (30.8%), 3 (42.9%), and 1 (16.7%) patients in the respective cohorts. Clinical outcomes favored the nivolumab plus ipilimumab arm compared with nivolumab alone, including an overall response rate of 57% (4 of 7 patients; 90% CI, 23%-87%) versus 0% (0 of 6 patients; 90% CI, 0%-39%), median progression-free survival of 11.6 months (90% CI, 4.5 months to not reached) versus 2.7 months (90% CI, 1.3-4.7 months), and median OS of 41.6 months (90% CI, 4.5 months to not reached) versus 4.7 months (90% CI, 2.0-16.2 months) (all P < .05). With combination immunotherapy, 3-year OS was 57% (90% CI, 23%-81%), with 2 patients alive after 42.7 months without progression and negative PET.In this first prospective trial investigating the combination of SBRT and immunotherapy for HCC, multimodal therapy demonstrated acceptable safety. SBRT with nivolumab plus ipilimumab compared favorably to outcomes of immunotherapy alone and warrants further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LingC完成签到,获得积分10
刚刚
刚刚
嘻嘻完成签到,获得积分10
刚刚
1秒前
1秒前
1秒前
华仔的应助被Zzzz采纳,获得10
1秒前
2秒前
4秒前
zztOvO发布了新的文献求助10
4秒前
4秒前
科研木头人完成签到 ,获得积分10
6秒前
汉堡包的应助被学术混子采纳,获得10
6秒前
Z20251040501发布了新的文献求助10
7秒前
8秒前
Ava的应助被孤独采纳,获得10
8秒前
斯文曼波发布了新的文献求助10
8秒前
宋清华完成签到,获得积分10
9秒前
桐桐的应助被sy采纳,获得10
9秒前
10秒前
细心天德发布了新的文献求助10
11秒前
希望天下0贩的0的应助被小鱼采纳,获得10
11秒前
YUEYUEHENCHEN发布了新的文献求助10
11秒前
fireulc完成签到,获得积分10
11秒前
喜悦绮波完成签到,获得积分10
11秒前
英姑的应助被dlsq采纳,获得30
11秒前
霍则风发布了新的文献求助60
11秒前
八爪鱼发布了新的文献求助10
12秒前
房子完成签到,获得积分10
13秒前
情怀的应助被机灵的听荷采纳,获得10
13秒前
fireulc发布了新的文献求助10
13秒前
田様的应助被优美的豪英采纳,获得10
13秒前
复杂的绮兰完成签到,获得积分10
14秒前
笑傲江湖完成签到,获得积分10
14秒前
14秒前
小芃完成签到,获得积分10
14秒前
xlp完成签到,获得积分10
14秒前
ccc完成签到 ,获得积分10
15秒前
Expelliarmus发布了新的文献求助10
15秒前
贝壳完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187918
求助须知:如何正确求助?哪些是违规求助? 9575850
关于积分的说明 21843829
捐赠科研通 7785760
什么是DOI,文献DOI怎么找? 3435128
关于科研通互助平台的介绍 2559501
邀请新用户注册赠送积分活动 2482027